Publications

Journal Article Epublish 27 citations
Electronic publication date
January 30, 2021

View on Pubmed.gov 32586280 | View on doi.org 10.1186/s12885-...

MiR-34c downregulation leads to SOX4 overexpression and cisplatin resistance in nasopharyngeal carcinoma.

Search for publications in this journal BMC Cancer - 20(1):597

Abstract

BACKGROUND

A major cause of disease-related death in nasopharyngeal carcinoma (NPC) is the development of distant metastasis (DM) despite combination chemoradiotherapy treatment. We previously identified and validated a four microRNA (miRNA) signature that is prognostic for DM. In this study, characterization of a key component of this signature, miR-34c, revealed its role in chemotherapy resistance.

METHODS

Two hundred forty-six NPC patient biopsy samples were subject to comprehensive miRNA profiling and immunohistochemistry (IHC). Two human normal nasopharyngeal cell lines (immortalized; NP69 and NP460), as well as the NPC cell line C666-1, were used for miR-34c gain-of-function and loss-of-function experiments. Signaling pathways were assessed using quantitative real-time PCR (qRT-PCR) and Western blot. Cell viability was measured using the ATPlite assay.

RESULTS

MiR-34c was downregulated in NPC patient samples, and confirmed in vitro to directly target SOX4, a master regulator of epithelial-to-mesenchymal transition (EMT). MiR-34c downregulation triggered EMT-representative changes in NP69 and NP460 whereby Snail, ZEB1, CDH2, and SOX2 were upregulated, while Claudin-1 and CDH1 were downregulated. Phenotypically, inhibition of miR-34c led to cisplatin resistance, whereas miR-34c over-expression sensitized NPC cells to cisplatin. TGFβ1 decreased miR-34c and increased SOX4 expression in vitro. The TGFβ receptor 1 inhibitor SB431542 reduced SOX4 expression and increased cisplatin sensitivity. Finally, IHC revealed that lower SOX4 expression was associated with improved overall survival in chemotherapy-treated NPC patients.

CONCLUSION

miR-34c is downregulated in NPC. Repression of miR-34c was shown to increase SOX4 expression, which leads to cisplatin resistance, while TGFβ1 was found to repress miR-34c expression. Taken together, our study demonstrates that inhibition of the TGFβ1 pathway could be a strategy to restore cisplatin sensitivity in NPC.

References

Oncotarget. 2015 Feb 28;6(6):4537-50

Cancer Res. 2017 Jun 15;77(12):3244-3254

Pigment Cell Melanoma Res. 2016 Jul;29(4):453-8

Prostate Cancer Prostatic Dis. 2013 Dec;16(4):301-7

Cited by 27 citations (total)

Journal Article Review

MiRNA signatures in nasopharyngeal carcinoma: molecular mechanisms and therapeutic perspectives.

Electronic publication date January 8, 2024

Search for publications in this journal Am J Cancer Res

Yan Chen [...] Yingchun He et al.

Nasopharyngeal carcinoma (NPC) is a prevalent cancerous tumor that affects the head and neck region. Recent studies have provided compelling...

Journal Article Review

Overcoming therapeutic resistance to platinum-based drugs by targeting Epithelial-Mesenchymal transition.

Electronic publication date November 1, 2022

Search for publications in this journal Front Oncol

Xirui Duan [...] Ke Xie et al.

Platinum-based drugs (PBDs), including cisplatin, carboplatin, and oxaliplatin, have been widely used in clinical practice as mainstay treatments for various...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances